Antimicrobial Compositions Patent Application

The USPTO has published a patent application (US20260083126A1) for antimicrobial compositions containing organosulfur compounds. The application, filed on September 8, 2023, describes compounds useful for treating microbial infections and for cleaning, disinfecting, or agricultural use.

Chemical Compound with Triazine Group and Production Method

The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.

USPTO Patent for Therapeutic Compounds Treating Cancer

The USPTO has published patent application US20260085059A1 for therapeutic compounds and methods of use in treating cancer. The patent was assigned to Servier Pharmaceuticals LLC and lists Samuel V. Agresta et al. as inventors. The application was filed on May 7, 2025.

Proteoglycan Mimetics for Wound Healing and Angiogenesis

The USPTO has published a new patent application, US20260083852A1, detailing proteoglycan mimetics for enhanced wound healing and angiogenesis. The application describes compounds designed to support tissue regeneration and promote vascular repair, potentially limiting systemic exposure to VEGF activity.

Patent for Radiation Dose Enhancement and Tumor Delineation

The USPTO has published a new patent application (US20260083850A1) for compounds, compositions, and methods related to radiation dose enhancement and tumor delineation. The application, assigned to the University of Connecticut, focuses on using barium nanoparticles for improved radiation therapy and tumor identification.

Modified T-Cells for Bladder Cancer Treatment Application

The USPTO has published a patent application (US20260083849A1) detailing a method for treating bladder cancer using modified immunoresponsive cells. The application was filed on September 7, 2023, and is related to therapeutic applications in oncology.

CAR T-cell therapy combined with BTK inhibitors for cancer

The USPTO has published a new patent application (US20260083848A1) detailing a combination therapy for cancer treatment. The application describes the use of CAR T-cell therapy with BTK inhibitors for treating hematological malignancies. This represents a new disclosure in the field of cancer therapeutics.

Patent Application: T-cell receptors target mutant RAS for cancer treatment

The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

USPTO Patent Application: Polynucleotides Targeting NR4A3

The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.

Cellicure, Inc. Patent Application for Engineered Immune Cells

The USPTO has published a patent application (US20260083845A1) filed by Cellicure, Inc. on September 22, 2023. The application details engineered immune cells, specifically chimeric antigen receptors (CARs) for enhanced killing activities, primarily targeting cancer treatment.